Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
David B Clemow, Chris Bushe, Michele Mancini, Michael H Ossipov & Himanshu Upadhyaya. (2017) A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities. Neuropsychiatric Disease and Treatment 13, pages 357-371.
Read now
Read now
Articles from other publishers (18)
Mona El-Sayed Hervig, Chiara Toschi, Anders Petersen, Signe Vangkilde, Ulrik Gether & Trevor W. Robbins. (2022) Theory of visual attention (TVA) applied to rats performing the 5-choice serial reaction time task: differential effects of dopaminergic and noradrenergic manipulations. Psychopharmacology 240:1, pages 41-58.
Crossref
Crossref
Michael Rösler, Wolfgang Retz & Daniel Turner. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
4543
4560
.
Michael Rösler, Wolfgang Retz & Daniel Turner. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
18
.
Benjamin Vidal, Marine Droguerre, Ludovic Venet, Luc Zimmer, Marco Valdebenito, Franck Mouthon & Mathieu Charvériat. (2020) Functional ultrasound imaging to study brain dynamics: Application of pharmaco-fUS to atomoxetine. Neuropharmacology 179, pages 108273.
Crossref
Crossref
W. Retz, P. Retz-Junginger, S. Davydenko & M. Rösler. (2020) Medikamentöse Therapie der Aufmerksamkeitsdefizit‑/Hyperaktivitätsstörung im ErwachsenenalterPharmacotherapy of attention deficit hyperactivity disorder in adults. Der Nervenarzt 91:7, pages 583-590.
Crossref
Crossref
Daniela Zmeškalová. (2020) Atomoxetine. Psychiatrie pro praxi 21:1, pages 47-52.
Crossref
Crossref
Gianmaria Zita & Giovanni Migliarese. (2020) La doppia diagnosi ADHD e SUD. MISSION:53, pages 10-16.
Crossref
Crossref
Abhinaba Ghosh, Saibal Das, Sapan Kumar Behera, Kirubakaran Ramakrishnan, Sandhiya Selvarajan, Preeti Kandasamy & N Sreekumaran Nair. (2020) Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson’s Disease Patients with Cognitive Deficits: A Meta-Analysis. Parkinson's Disease 2020, pages 1-8.
Crossref
Crossref
Michael Rösler & Wolfgang Retz. (2020) Medikamentöse Therapie der ADHS bei Erwachsenen. PSYCH up2date 14:01, pages 59-75.
Crossref
Crossref
Carly B. Warner, Andreina A. Ottman & Jamie N. Brown. (2018) The Role of Atomoxetine for Parkinson Disease–Related Executive Dysfunction. Journal of Clinical Psychopharmacology 38:6, pages 627-631.
Crossref
Crossref
Dora Wynchank, Denise Bijlenga, Aartjan T. Beekman, J. J. Sandra Kooij & Brenda W. Penninx. (2017) Adult Attention-Deficit/Hyperactivity Disorder (ADHD) and Insomnia: an Update of the Literature. Current Psychiatry Reports 19:12.
Crossref
Crossref
Wu-Chien Chien, Chi-Hsiang Chung, Fu-Huang Lin, Chin-Bin Yeh, San-Yuan Huang, Ru-Band Lu, Hsin-An Chang, Yu-Chen Kao, Wei-Shan Chiang, Yu-Ching Chou, Chang-Huei Tsao, Yung-Fu Wu & Nian-Sheng Tzeng. (2017) The risk of injury in adults with attention-deficit hyperactivity disorder: A nationwide, matched-cohort, population-based study in Taiwan. Research in Developmental Disabilities 65, pages 57-73.
Crossref
Crossref
Tian Lan, Xiao-Xia Hu, Bing-Qing Liang, Wen-He Pan, Quan Zhou, Ling-Jing Yuan & Guo-Xin Hu. (2016) The Effect of Myricetin on Pharmacokinetics of Atomoxetine and its Metabolite 4-Hydroxyatomoxetine In Vivo and In Vitro. European Journal of Drug Metabolism and Pharmacokinetics 42:2, pages 261-268.
Crossref
Crossref
David B. Clemow, Allen W. Nyhuis & Rebecca L. Robinson. (2016) Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention‐Deficit/Hyperactivity Disorder. CNS Neuroscience & Therapeutics 22:12, pages 970-978.
Crossref
Crossref
Peter R. BieckMark LeibowitzD. Richard LachnoEdouard LedentRobert PadichStan Jhee. (2016) Dihydroxyphenylglycol as a Biomarker of Norepinephrine Transporter Inhibition by Atomoxetine. Journal of Clinical Psychopharmacology 36:6, pages 675-683.
Crossref
Crossref
Lucie Barateau, Régis Lopez & Yves Dauvilliers. (2016) Management of Narcolepsy. Current Treatment Options in Neurology 18:10.
Crossref
Crossref
Linda A. Wietecha, David B. Clemow, Andrew S. Buchanan, Joel L. Young, Elias H. Sarkis & Robert L. Findling. (2016) Atomoxetine Increased Effect over Time in Adults with Attention‐Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double‐Blind, Placebo‐Controlled, Randomized Trials. CNS Neuroscience & Therapeutics 22:7, pages 546-557.
Crossref
Crossref
Lucie Barateau, Régis Lopez & Yves Dauvilliers. (2016) Treatment Options for Narcolepsy. CNS Drugs 30:5, pages 369-379.
Crossref
Crossref